Arecor Therapeutics (AREC) Competitors GBX 62 -1.50 (-2.36%) As of 11:42 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock AREC vs. MPH, HVO, ORPH, REDX, ETX, SBTX, COS, C4XD, FUM, and DDDDShould you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), Futura Medical (FUM), and 4D pharma (DDDD). These companies are all part of the "biotechnology" industry. Arecor Therapeutics vs. Its Competitors Mereo BioPharma Group plc (MPH.L) hVIVO Open Orphan Redx Pharma e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery Futura Medical 4D pharma Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends. Does the media refer more to MPH or AREC? In the previous week, Arecor Therapeutics had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for Arecor Therapeutics and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score. Company Overall Sentiment Mereo BioPharma Group plc (MPH.L) Neutral Arecor Therapeutics Neutral Is MPH or AREC more profitable? Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Arecor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group plc (MPH.L)N/A N/A N/A Arecor Therapeutics -176.89%-118.67%-37.31% Do institutionals and insiders hold more shares of MPH or AREC? 44.1% of Arecor Therapeutics shares are owned by institutional investors. 25.3% of Arecor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, MPH or AREC? Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than Arecor Therapeutics. Arecor Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/AArecor Therapeutics£6.04M3.88-£10.68M-£28.30-2.19 SummaryArecor Therapeutics beats Mereo BioPharma Group plc (MPH.L) on 5 of the 9 factors compared between the two stocks. Get Arecor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AREC vs. The Competition Export to ExcelMetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£23.41M£150.08M£5.78B£3.18BDividend YieldN/A3.74%3.95%5.04%P/E Ratio-2.193.8531.26166.92Price / Sales3.883,963.89454.13448,413.15Price / Cash5.0713.1937.7327.93Price / Book3.7459.4710.046.35Net Income-£10.68M-£90.99M£3.27B£5.89B7 Day Performance-2.00%10.34%3.17%0.77%1 Month Performance10.71%11.73%4.34%49.50%1 Year Performance-25.43%303.51%44.12%141.61% Arecor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARECArecor TherapeuticsN/AGBX 62-2.4%N/A-27.0%£23.41M£6.04M-2.1910Gap DownMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/A-0.2150Gap DownHVOhVIVO2.4496 of 5 starsGBX 10.23-0.2%GBX 28+173.8%-66.0%£72.35M£68.74M4.22N/ANews CoverageORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179REDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 14.32+2.3%N/A+13.9%£32.70M£1.56M-8.8011COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeFUMFutura MedicalN/AGBX 9.70-1.6%N/A-73.6%£30.23M£8.68M-8.0012Gap DownDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106 Related Companies and Tools Related Companies Mereo BioPharma Group plc (MPH.L) Alternatives hVIVO Alternatives Open Orphan Alternatives Redx Pharma Alternatives e-therapeutics Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives Futura Medical Alternatives 4D pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AREC) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access